Development finance ‘paramount’ in fight against AMR pandemic
In recent decades, the biological phenomenon known as antimicrobial resistance (AMR) – when bacteria, viruses, fungi and parasites become resistant to existing medicines – has resulted in the majority of our antimicrobial therapies becoming obsolete, leaving the world’s population susceptible to an ever-increasing range of infections. As a result, the possibility of a bacterial pandemic is today widely recognised as an imminent threat.
In a bid to combat the issue, the European Investment Bank (EIB) and BioVersys, a Swiss clinical-stage pharmaceutical company developing treatments for multidrug-resistant bacterial infections, last month signed a €20 million ($24.4 million) venture debt transaction. The financing supports the company’s research and development of a diverse pipeline of drugs that address AMR.
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.